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This newsletter was jointly developed and 
subject to editorial review by Jefferson 
School of Population Health and Lilly 
USA, LLC, and is supported through 
funding by Lilly USA, LLC. The content 
and viewpoints expressed are those of the 
individual authors, and are not necessarily 
those of Lilly USA, LLC or the Jefferson 
School of Population Health.
The sultry summer day on campus 
belied the atmosphere inside as 
the proceedings of an expert panel 
meeting, titled Creating a Framework 
for Accountable Care, unfolded. The 
conveners – Jefferson’s School of 
Population Health and the team from 
Eli Lilly and Company – and panelists 
were enthusiastic about the Affordable 
Care Act’s (ACA) emphasis on 
accountability and expressed optimism 
about the sea change already under way 
in US health care delivery. 
Fast forward to early November, 
several weeks after the rocky launch 
of Healthcare.gov. True, the electronic 
enrollment technology fell woefully 
short. True, some of us will not be able 
to continue buying insurance plans that 
fail to provide coverage that meets the 
ACA’s minimum standards. But, as 
with any large, complex initiative, fits 
and starts are to be expected – the real 
danger lies in focusing too narrowly on 
the glitches. 
To my mind, this first installment of our 
new Prescriptions for Excellence in Health 
Care series could not come at a more 
opportune time because it takes a broad 
view of another important aspect of the 
law (ie, accountable care), celebrates 
some early successes, and explores new 
approaches to future challenges. 
The first article, “Accountable Care 
2013: Are We There Yet?,” describes the 
journey to “there” by exploring manifold 
paths to potential failure or imminent 
success. In “Creating a Framework for 
Accountable Care: Ensuring Product 
Value,” we delve into an often ignored 
aspect of accountability – the need for 
manufacturers of health care devices and 
pharmaceuticals to demonstrate clinical 
and economic effectiveness relative to 
comparable alternatives. 
My personal favorite title is “Moneyball 
for Health Care.” The premise of the 
article is that US health care should 
follow American baseball’s example 
Editorial
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and begin to look at data in different, 
smarter ways that will impact the 
bottom line. Last but not least, 
“Redefining Care Management to 
Address Increasing Fragmentation in 
Health Care” is a compelling reminder 
that integration is an essential 
ingredient in accountable care. 
The “blame games” now playing out 
at all levels of government and in the 
media make a clear case for building 
more accountability into our systems. 
Accountability leaves no room for blame. 
As always, I welcome feedback from 
our readers at david.nash@jefferson.edu.
This issue of Prescriptions for 
Excellence in Health Care focuses on 
a number of important aspects of 
Accountable Care Organizations 
(ACOs) and what it will take to 
make them successful in the United 
States. Without question, we have 
opportunities to improve the quality 
of our health care system while better 
managing costs. Accountable care in 
the United States shows promise, but 
we must be mindful to implement 
those incentives that will lead to the 
outcomes and costs that we all want.
At the end of 2013, more than 
360 Medicare ACOs had been 
established, serving more than 5.3 
million Medicare beneficiaries.1 
Although it has been less than 4 
years since the ACA was signed into 
law, almost 10% of the Medicare 
population now receives health care 
from an ACO. 
As noted in the Centers for 
Medicare & Medicaid Services’ 
(CMS) Medicare Shared Savings 
Program (MSSP) Proposed Rule 
(2011), in risk-based arrangements 
wherein “providers of services 
and suppliers have an increased 
motivation to control spending 
and achieve efficiencies, it would 
be reasonable to anticipate an 
increase in negative incentives 
such as incentives to stint on care 
or undersupply services, [and] 
shift costs,” among other things.2 
ACO metrics, particularly within 
the MSSP, may create misaligned 
incentives relative to innovative 
technologies. Specifically, new 
technology costs likely are not 
included in the benchmark cost 
and any potential savings associated 
with the new technology may not 
be realized within the relevant time 
window of measurement. 
Ensuring access to innovative 
new technologies is critical to the 
long-term success of our health 
care system. It follows that ACO 
metrics should not disincentivize the 
appropriate use of new technologies. 
The range of options available to 
ensure beneficiary access to new 
technologies includes: 
•  Creating reimbursement carve-
outs for new technologies.
•  Monitoring ACO adoption of 
new technologies.
•  Encouraging ACOs to address 
new technologies in their clinical 
guidelines. 
•  Fostering adherence to 
compendia guidelines to ensure 
appropriate beneficiary access to 
new technologies. 
Carve-Outs 
One way to ensure that patients 
continue to have access to innovative 
medical technologies is to carve 
them out of both the benchmark 
and performance year expenditures 
for ACOs. When the decision 
to use such therapies is removed 
from the calculation of the ACO’s 
expenditures for purposes of 
determining shared savings, there 
is no incentive to lower costs by 
denying patients access to them. 
Quality Assessment  
The development and implementation 
of quality measures to assess an 
entity’s adoption of new technologies 
is another approach to ensuring 
appropriate beneficiary access to 
innovative technologies. Monitoring 
adherence to new technology quality 
measures as well as ACO access levels 
for new technologies will help reduce 
inappropriate restrictions on medical 
innovation.
Practice Guidelines 
Development of evidence-based 
medical practices is important 
A Message from Lilly
Ensuring Access to New Technology in Accountable Care Organizations
By Derek L. Asay 
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for any ACO, regardless of its 
participation in the MSSP. CMS’ 
MSSP final rule requires Medicare 
ACOs to develop evidence-based 
medical practices or clinical 
guidelines for delivering coordinated 
care, especially for diagnoses 
with potential for significant 
quality improvements and cost 
savings.3 Beneficiary access to new 
technologies should be addressed in 
these guidelines and processes. 
Compendia Guidelines 
ACOs’ evidence-based clinical 
guidelines should adhere to 
recognized compendia guidelines 
for the use of drugs and biologics. 
A drug compendia guideline lists 
appropriate uses of drugs and 
biologics as defined in clinical 
practice guidelines based on 
the evaluation of evidence from 
scientific literature, integrated with 
expert judgment in a consensus-
driven process. 
The incentive to reduce costs 
that is inherent in any risk-based 
arrangement may lead to negative 
consequences with regard to 
decisions about the care beneficiaries 
receive and their access to specific 
procedures and new technologies. 
Therefore, steps must be taken 
to ensure that ACO-generated 
“savings” reflect real quality and 
efficiency gains. Most importantly, 
we must ensure that the best interest 
of the patient is at the forefront 
when all clinical decisions, including 
treatment recommendations and 
prescribing decisions, are made.
Paramount to the integrity of any 
ACO program is monitoring how 
savings are generated (eg, identifying 
and understanding any changes in 
coding patterns). Details regarding 
savings generated and other pertinent 
information concerning an ACO’s 
operation and performance should be 
made publicly available. Transparency 
will help ensure against inappropriate 
cost-saving practices (eg, cost-
shifting), facilitate the sharing of best 
practices, and hold ACOs accountable 
for producing savings through quality-
driven changes.
ACOs are viewed as leaders in 
health care reform for their use of 
innovative service delivery models. 
They also should be seen as leaders 
in evaluating and adopting innovative 
medical technologies. By doing so, 
they will keep patients at the center of 
everything that is done in health care. 
Derek L. Asay is Senior Director, 
Government Strategy, Federal Accounts 
and Quality for Lilly USA, LLC, the 
U.S. affiliate of Eli Lilly and Company.
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Accountable care is an idea whose time 
has come. Or is it? Initiatives are under 
way on several fronts to build health 
care systems that are accountable for 
their outcomes and costs, but we have 
been here before. Will accountable 
care finally transform American health 
care, or are today’s efforts just another 
chapter in a long-running saga?
The Vision of Accountable Care 
At its core, the call for accountable 
care is a response to 2 fundamental 
and interrelated shortcomings in the 
American health care system. One is 
the relentless rise in costs. The other is 
a pervasive inconsistency in quality.
In terms of costs, the United States 
has the most expensive health care 
system in the world. We spend at least 
50% more per capita on health care 
than any other developed country, 
and almost twice as much as several 
of them.1 Moreover, our rate of 
spending growth is accelerating faster 
than anywhere else. Health care now 
consumes more than 17% of the 
American economy.2 It is expected to 
exceed 20% within the next few years.3
Despite this level of spending, our 
health outcomes are no better and, in 
some regards, are worse than those 
in much of the developed world. The 
United States trails several other 
developed countries on numerous 
Accountable Care 2013: Are We There Yet?
By Robert I. Field, JD, MPH, PhD
(continued on page 4)
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measures including life expectancy, 
infant mortality, and mortality 
attributable to health care.4 Clearly, we 
are doing something wrong.
In terms of quality, the American health 
care system is plagued by errors that 
injure and kill thousands of patients 
every year, causing as many as 100,000 
deaths annually by one estimate.5 
Medical practice varies widely across 
regions of the country and even within 
regions, producing dramatic disparities 
in costs without discernible differences 
in outcomes.6 The obvious conclusion 
is that good medicine is practiced 
inconsistently at best.
The vision of accountable care is to 
address these problems by restructuring 
relationships among providers,7 thereby 
eliminating incentives that promote 
inefficient and ineffective care and 
replacing them with rewards that 
encourage accountability for the costs 
incurred and outcomes produced. 
This, it is hoped, will rid the system of 
clinical behavior that inflates costs and 
ignores evidence of effectiveness.
Accountable Care Initiatives of the Past 
The movement for accountable care 
first took root on a wide scale in the 
1990s with the creation of what were 
known as “integrated delivery systems” 
or IDSs. These collections of different 
providers within a single organizational 
structure typically included hospitals, 
physicians, and providers of ancillary 
services. They tried to align incentives 
and oversee care to promote efficiency 
and effectiveness.8
Versions of IDSs had existed for 
decades, with some led by hospitals (eg, 
the Mayo Clinic, the Cleveland Clinic, 
Geisinger Health System) and others 
by insurance companies (eg, Kaiser-
Permanente). The new iterations of 
the 1990s tried to integrate care with 
more dispersed provider networks. 
Although some of these systems made 
major strides in coordinating care, the 
vision of true provider accountability 
remained largely unfulfilled. Too often, 
incentives were inconsistently and 
inappropriately aligned, and many 
constituent providers continued to  
be compensated based on the volume, 
rather than the quality, of services  
they rendered.9
Reasons Why Accountable Care May 
Succeed This Time 
The movement for accountable care 
has reemerged in the last few years 
with renewed vigor. Will it turn out 
differently this time? There are several 
reasons to think that it will.
First and foremost, information 
technology has advanced tremendously 
since the 1990s and is now 
more capable of supporting care 
coordination and oversight. Medical 
record systems are more advanced and 
new technological capabilities, such as 
home monitoring of clinical indicators, 
have emerged.10 The Internet, which 
was just developing as a commercial 
tool in the 1990s, has greatly 
expanded the horizons of electronic 
communication.
Coupled with these advances is an 
increased willingness of physicians and 
other clinicians to use technology. The 
relative comfort with electronic records 
and other technological applications 
can be attributed to more hands-on 
experience among providers in general 
and greater technological savvy among 
a new generation of physicians. 
New physicians also are more 
accustomed to alternative 
compensation plans that reward 
outcomes rather than volume of 
services. Their expectations are less 
likely to be linked to the old way of 
doing things. At the same time, a 
growing number of large payers have 
taken active roles in crafting innovative 
reimbursement plans.11
Finally, today’s movement for 
accountable care is supported by major 
new government initiatives. The 
Health Information Technology for 
Economic and Clinical Health Act 
(2009) offers physicians significant 
financial incentives for adopting 
electronic records and using them in a 
meaningful way.12 The Affordable Care 
Act (2010) promotes the formation  
of accountable care organizations – 
alliances of hospitals, physicians, and 
other providers that build on the 
IDS concept of the 1990s to enhance 
quality and control costs.13
Reasons Why Accountable Care May  
Still Fall Short 
Although these developments are cause 
for optimism, clouds still linger on 
accountable care’s horizon. A major 
threat is the lack of sufficient primary 
care capacity.14 Through their role in 
overseeing all aspects of care, primary 
care providers serve as linchpins for 
care coordination in many accountable 
care systems.15 However, the number of 
American physicians entering primary 
care remains low and shows no signs of 
increasing. Allied health professionals 
(eg, nurse practitioners, physician 
assistants), who could fill some of the 
need, require years of training. 
Accountable care also faces some of the 
same social and professional resistance 
that has stymied it in the past. The 
American health care system is huge 
and, like most massive enterprises, 
resistant to change. Many physicians 
continue to cherish their autonomy 
and resent the oversight that care 
coordination can impose. Although a 
new generation of physicians may be 
more accepting of alternative practice 
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paradigms, they do not yet dominate 
the profession.
Finally, fee-for-service reimbursement 
remains the norm for much of 
American health care.16 Innovations 
abound, but many large payers, 
including Medicare, continue to 
pay physicians largely based on the 
number, rather than the quality, of 
services they render. It is difficult for 
a provider system to restructure its 
incentives when the external funding 
environment remains mired in the past.
The Bottom Line: Cause for  
Cautious Optimism 
What should we expect from the latest 
movement for accountable care? Has 
its time finally arrived? Although 
challenges remain, the balance of 
positive factors suggest that it has. 
Information technology has grown 
in sophistication and now offers 
many of the capabilities necessary for 
coordinating care systems. Providers 
are more accepting of accountability 
and the limits on clinical autonomy 
that it can impose. Many major 
payers, including insurance companies, 
large employers, and Medicare, are 
testing innovative approaches to 
reimbursement. And government 
policy is more actively supporting and 
encouraging accountable care than it 
has at any time in the past.
The dream of accountable care is 
getting closer to reality every day.  
It may take longer to reach fruition 
than many had hoped, but its 
widespread implementation is within 
reach. Even the most obstinate of 
systems can eventually change its 
antiquated ways, and American health 
care is no different.
Robert I. Field, JD, MPH, PhD, is 
Professor of Law and Professor of Health 
Management and Policy at Drexel 
University. He can be reached at:  
robert.field@drexel.edu. 
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The US health care system is currently 
undergoing what ultimately will be 
a radical transformation driven by 
unsustainable cost increases, increasing 
regulation, and shifting power 
relationships among payers, providers, 
physicians, and patients. Technology 
advances are accelerating the pace 
of innovation, while rising costs and 
demands for affordable health care and 
greater transparency are challenging 
the economics and traditional business 
assumptions of the industry. 
At the same time, health policy shifts 
brought about by the Patient Protection 
and Affordable Care Act are placing 
increased accountability and cost 
pressures on providers to improve patient 
safety, quality of care, and consistency 
of care delivered. In response, payers 
(government and private) are actively 
engaged in changing the way physicians 
and hospitals are paid. These changes 
include greater emphasis by payers and 
other stakeholders on requiring value 
for payment (eg, pay for performance, 
bundled payment initiatives). 
Creating a Framework for Accountable Care: Ensuring Product Value 
By Rita E. Numerof, PhD 
(continued on page 6)
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In the broader context of constrained 
resources, all those who pay for care – 
including providers, payers, and 
consumers/patients – have become more 
focused on the “value” they receive. 
In addition, an increasingly educated 
and information-driven generation 
is demanding – and receiving – more 
data about the quality and outcomes 
associated with specific institutions, 
procedures, and individual doctors. 
Providers, payers, and consumers 
alike are escalating their demands for 
improved economic and clinical value. 
In addition, the trend of health care 
provider consolidation and physician 
employment has gained momentum over 
the past several years. Integrated systems 
and Accountable Care Organizations 
likely will further reduce suppliers’ 
access to physicians as they join larger 
group practices or become employed by 
hospital-based organizations. 
Collectively, these pressures are causing 
providers to impose more structure 
on care delivery in an effort to reduce 
cost and improve quality – in effect, 
improving their organizations’ ability to 
provide “accountable care.” As a practical 
matter, hospital leaders must focus on 
understanding the actual cost of care and 
how their organizations will charge and 
be paid for services. As new payment 
systems are implemented, there is more 
emphasis on links between payment 
and quality; for example, Medicare’s 
refusal to reimburse hospitals for 
services associated with “never events.” 
As payment is increasingly linked to 
quality, administrative and clinical 
leaders must find new ways to reduce 
unnecessary variation in medical practice 
and streamline operations, including the 
supply chain, both to improve care and 
manage costs more effectively. 
The push for accountability in 
delivering higher quality care at lower 
costs has significant implications 
for manufacturers; for instance, the 
diminished role of individual physicians 
in decision making about products. 
Going forward, committees will make 
decisions about which products to use. 
There will be fewer but larger provider 
customers, requiring more sophisticated 
sales capabilities on the part of 
manufacturers. With greater transparency 
and more links between payment and 
outcomes, there also will be increased 
pricing pressure on product companies. 
Product selection will not simply 
be focused on price; rather it will be 
on selecting products with clearly 
demonstrated benefits over competitor 
products. Manufacturers should 
anticipate that providers will engage in 
aggressive formulary management and 
give preference to those products that 
demonstrate value in terms of safety, 
efficacy, and cost. In short, manufacturers 
must be able to demonstrate the economic 
and clinical value of their products 
compared to alternatives. 
To demonstrate a product’s clinical 
value, manufacturers must have the 
ability to provide data on the value of 
a new product in terms of its potential 
to improve patient outcomes, patient 
management, and overall treatment 
costs. This perspective requires a 
broader view of a product in the context 
of clinical use, and its potential impact 
on economic and clinical outcomes. 
Fully identifying the potential value of 
products requires looking beyond product 
attributes such as physician ease of use 
or a specific product attribute. Focusing 
narrowly on individual physicians’ 
interests often leads to head-to-head 
comparisons with similar products and, 
at times, overemphasis on single attribute 
superiority. Instead, new products should 
be evaluated on how they potentially 
improve current treatment regimens for 
the condition addressed, save costs, and 
improve outcomes. 
Example: For comparative purposes, 
determining the potential of a new drug as 
a substitute for multiple drugs in a current 
therapeutic regimen could be of great 
value. Demonstrating equivalent efficacy 
(vs. superiority) may be sufficient if the 
product has an improved dosing frequency 
and improved patient adherence, or a 
reduction in the number of medications or 
physician visits required for treatment. 
Such an approach requires the 
integration of a broader relevant 
stakeholder perspective on value wherein 
every market need and product benefit 
is evaluated through the lens of “What 
is it worth?” This is especially true when 
comparing a new product to generics 
and other products that already exist in 
the marketplace. Strengthening a value 
proposition to providers – and payers – 
requires data that demonstrate reduced 
costs and/or improved clinical outcomes 
compared to alternatives. Successful 
manufacturers must demonstrate the 
value of their products in efforts to 
achieve accountable care. 
As manufacturers become more 
sophisticated in presenting economic 
and clinical value data to providers, 
hospitals will need to adopt processes 
for evaluating new products. Because 
the health care delivery team will be 
tasked with managing the internal 
decision-making process regarding 
product decisions, they must understand 
what value a new product will add to 
an existing treatment regimen and 
effectively evaluate the evidence on 
products. Having such processes in 
place may create new opportunities for 
hospitals to partner with manufacturers. 
Rita E. Numerof, PhD, is President of 
Numerof & Associates, Inc. She can be 
reached at: rnumerof@nai-consulting.com.
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Everyone agrees that US health care is 
expensive and that there must be a better 
way. However, there is considerable 
uncertainty regarding the actual root 
cause of the problems and no clear 
solutions. Perhaps there is an opportunity 
to use data differently to implement 
strategies that can move the system 
forward one piece at a time.
By any measure, we spend more on health 
care than any other country, and yet the 
outcomes we achieve are disappointing. 
Confounding variables, including 
our unhealthy lifestyles, social and 
environmental factors, and malpractice 
issues, cloud the degree to which the 
health care system itself is producing 
suboptimal health outcomes. At the same 
time, we hear anecdotes about the world’s 
elite flying to the United States because 
of our superior outcomes for acute care. 
How can we make sense of this?
Reconciling these paradoxical statements 
is confusing; however, a resolution may 
be found by using a different frame of 
reference. We have the best acute care 
system in the world but we fall woefully 
short at managing chronic disease and 
delivering preventive care. Because 
ours is chiefly an acute care system, our 
models fail to address the behavioral, 
social, and economic determinants that 
affect our health and result in additional 
cost. Our focus on services and 
procedures rather than the total patient 
has made us proficient at delivering high 
volume irrespective of total value.
An unlikely source may provide some 
insights for a path forward. I believe 
that baseball has something to teach us 
about using data to improve value. A 
recent evolution in the data elements 
used to predict wins in baseball has 
fundamentally transformed how teams 
value players. The innovative concept 
known as “moneyball” uses the data 
and information differently to assemble 
winning baseball teams for less money. 
When applied to health care, the concept 
would lead to our using data differently to 
take better care of patients for less money. 
Today, much that we do in acute care is 
based on flawed assumptions, similar to 
the way in which baseball players were 
valued. “Moneyball” for health care 
takes a different approach, using data 
and novel care models to ensure that 
patients get what they need when they 
need it (or even before they know they 
need it) (Figure 1), and resulting in 
better outcomes for a lower total cost. 
The key is delivering the right health 
care in the right amount at the right 
time. Today’s system is designed to 
deliver an abundance of acute care 
with insufficient attention to care 
coordination. For example, there is clear 
evidence that patients receive too many 
cardiac interventions that range from 
the rare criminal case (ie, stents placed 
in normal cardiac vessels) to the more 
common examples of stents placed in 
patients when the evidence suggests 
that medical management and lifestyle 
modification will result in similar 
outcomes.1 Although less acute care can 
produce better total outcomes, it is very 
challenging in our current environment 
to implement these changes. 
A Framework for “Moneyball”:  
Population Health 
To break out of the current mode, the 
starting point is having a population to 
manage. This is more important than 
building infrastructure and capabilities. 
Moneyball for Health Care 
By Brian Silverstein, MD
Figure 1.  Moneyball for Health Care
HRA, health risk assessment (continued on page 8)
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There must be a financial opportunity 
to improve care for this population 
and data must be available to make 
this possible. Self-insured employers 
already are well situated in this regard, 
and providers are seeking ways to 
acquire a population through risk-
based contracts and, more commonly, 
attribution in a fee-for-service contract. 
Once there is accountability for a 
population, the next step is to analyze 
and segment the population with an 
eye toward improving value. Some 
examples include identification of:
(1)  Gaps in care wherein patients’ 
needs for screening and their 
existing conditions can be 
improved (eg, vaccines, screening 
tests, checking HbA1C in all 
patients with diabetes).
(2)  Opportunities to improve outcomes 
through better care management 
(eg, implementing programs to 
avoid unnecessary emergency 
department visits and hospital 
admissions, assessing the value 
proposition for specific providers 
for a given clinical condition). 
Each of these interventions must be 
evaluated carefully to ensure that:
•  The segment has been correctly 
defined.
•  An opportunity exists for 
implementing the intervention in 
the defined population segment. 
•  There is sufficient time to achieve 
positive results.
Typically, it takes 5 to 10+ years to 
see a positive impact from screening 
programs whereas initiatives that target 
transitions of care often yield results in 
a few months.
Value-Driven Solutions and Interventions 
The earliest adopters of health care 
“moneyball” are employers. They 
focus on prevention and wellness and 
typically manage a population for a 
sufficient period of time to benefit 
from the investment. Because insurers 
and providers have been unable to 
manage cost increases, employers 
are shifting their focus to near-term 
opportunities that may make a large 
financial impact. For instance:
•  Creating care coordination benefits 
(eg, Boeing provided resources 
and created financial incentives 
for providers to deliver high-value 
health care).
•  Modifying benefit design to 
substantially increase cost sharing 
(eg, reference pricing) to drive 
patients from low-value to high-
value providers.
•  Creating programs that overlay 
benefits (eg, domestic travel 
benefits that enable patients to 
travel to a destination center for 
evaluation and treatment – at no 
charge to the employee – thereby 
reducing their variation in spend 
and outcomes).  
Providers may desire to play “moneyball” 
for population health, but success 
requires a distinct business model 
and different competencies than fee-
for-service care (Figure 2). The small 
number of providers with “risk” contracts 
have built systems to win in this model. 
Most providers are exploring ways to 
coordinate fee-for-service populations 
through innovative efforts that reap 
rewards for total value. Examples 
of these programs include bundled 
payments, comanagement agreements, 
patient-centered medical homes, and 
accountable care organizations  
(ACOs) (Figure 3). Although ACOs 
often are viewed as monolithic, there 
are factors that differentiate them – 
from the populations they serve 
(eg, Medicare, Medicaid, specific 
employers, commercially insured) to 
program operations (eg, attribution 
to benchmarks, provider networks). 
Although some ACOs assume 
financial risk (and have been doing so 
for many years before they were called 
ACOs), most are contracting fee-for-
service with a shared savings based on 
reduction in total expenses (upside-
only shared savings). 
There are various models, but the 
bottom line is that the most profitable 
Fee-for-Service Business Population Health
Customer People who are admitted (or use outpatient services)
Everyone who pays for coverage or is 
enrolled in a plan/program
Revenue Paid per unit of service Monthly fixed amount 
Expenses Primarily labor and facilities Health care services
Data Systems Cost accounting and billing Predictive models and care  management
Key to Success Keep occupancy high and expenses low
Increase management and monitoring 
to reduce unnecessary care
Figure 2.  Population Health – A Different Business
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Figure 3.  Care Delivery Transformation
Source: Centers for Medicare & Medicaid Services. Updates from CMS: value-based purchasing, ACOs and other initiatives, March 19, 
2012. http://www.ehcca.com/presentations/pfpsummit7/thompson_1.pdf . Accessed November 25, 2013.  ACO, accountable care organization; 
PCORI, Patient-Centered Outcomes Research Institute; REC, Regional Extension Center
option for high-volume providers is the 
least desirable – ie, the current one with 
unnecessary care. The math on shared 
savings will yield less aggregate revenue 
than the status quo. 
Half of the nation’s ACOs do not 
include a hospital partner – these 
organizations stand to benefit from 
a reduction in acute care volume 
without a reduction in their revenue. 
In addition, the technological and 
operational infrastructure required to 
fully implement the population health 
model is fundamentally different from 
volume health care. 
Providers must consider how to operate 
their core businesses as efficiently as 
possible while determining whether 
to make the substantial investments 
necessary to create a population health 
management business. The popular 
strategy of becoming a population 
health manager at the expense of your 
core business is a certain road to failure. 
Although there will be pressure on the 
acute care system, there is and will be 
value associated with better care. There 
is no bridge from volume to value as 
they are separate business models. 
The allure of population health 
also can lead to a desire to assemble 
components under a single umbrella 
organization. This is practical in the 
absence of willing partners in a market, 
but what happens when your hospital 
is more expensive and doesn’t deliver 
as high quality? Do you compromise 
the performance of the ACO at the 
expense of the system to keep the 
volume “in the family”? 
Having patients in high-deductible 
health plans plays an important 
supportive role in the success of provider 
value models. Although seemingly 
unrelated, patient engagement and 
malpractice liability are being addressed 
as patients with “money on the line” 
take more active roles in making 
decisions. Often, patients with high-
deductible plans become engaged and 
seek appropriate rather than maximum 
utilization. This helps providers to make 
sound recommendations without fear of 
litigation for avoiding a test or procedure.
Conclusion 
Most health care is local, and each market 
will evolve differently depending on supply 
and demand as well as the insurance 
market. There is a big opportunity today 
to play “moneyball.” Markets are moving 
rapidly as patients enroll in new insurance 
products and employers change benefits 
or create new programs. Providers can 
enter into shared savings arrangements 
and focus on care management and 
patient engagement and be rewarded for 
their results. Be ready to play the game 
differently if you want to win.
Brian Silverstein, MD, is President of  
HC Wisdom. He can be reached at:  
brian@silverstein.biz. 
Thanks to Emme Deland, MBA, Kevin 
Shah, MD, MBA and Jen Baker, MSHA for 
their editorial assistance. 
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A patient presents at a physician’s office 
with chest pain. On the basis of a chest 
X-ray, the physician believes the patient 
has a pneumothorax (collapsed lung) and 
calls the emergency department (ED) to 
notify the triage nurse that the patient is 
coming. The physician does not send the 
X-ray with the patient so, after assessment 
in the ED, the patient is taken for a 
second X-ray to confirm the diagnosis. 
While in the radiology department, the 
patient’s heart stops. Assuming that the 
referring physician’s diagnosis is correct, 
the emergency physician places a chest 
tube into the patient’s lung. When the 
patient’s condition does not improve, 
an electrocardiogram is performed 
revealing a myocardial infarction. The 
patient is referred to a cardiologist for 
an intervention but, because a history 
of allergies was not elicited in the ED, 
the patient has an allergic reaction 
to the contrast dye necessitating the 
administration of steroids. The steroids 
cause a stomach ulcer to hemorrhage. 
Eventually the patient goes home with 
many physical limitations and is unable 
to return to work. 
Although the foregoing scenario is 
hypothetical, this pattern of expensive 
care and poor outcomes – the result 
of care delivery fragmentation – is 
prevalent in the US health care system. 
Shih and colleagues summarize the 
issue well in their article for the 
Commonwealth Fund1: 
“The fragmentation of our delivery system 
is a fundamental contributor to the overall 
performance of the US health care system. 
•  Patients and families navigate 
unassisted across different providers and 
care settings, fostering frustrating and 
dangerous patient experiences;
•  Poor communication and lack of clear 
accountability for a patient among 
multiple providers lead to medical errors, 
waste, and duplication;
•  The absence of peer accountability, 
quality improvement infrastructure, and 
clinical information systems foster poor 
overall quality of care; and
•  High-cost, intensive medical intervention 
is rewarded over higher-value primary 
care, including preventive medicine and 
the management of chronic illness.” 
The result is that “the United States 
spends more than any other country 
on health care but still ranks in the 
bottom half of industrial countries 
in outcomes like life expectancy and 
infant mortality.”2 Enthoven defines 
fragmentation as “the systematic 
misalignment of incentives, or lack of 
coordination, that spawns inefficient 
allocation of resources or harm to 
patients. Fragmentation adversely 
impacts quality, cost, and outcomes.”3
A variety of health care services have 
been developed in the areas of wellness, 
disease management, and complex case 
management to address specific medical 
needs and reduce fragmentation. 
Wellness programs classify individuals 
into risk groups and apply educational 
interventions designed to help them 
stay “healthier,” be more engaged in 
their own health, and incur reduced 
costs. Disease management focuses on 
groups of individuals with a particular 
diagnosis and provides broad programs 
targeted to the condition. Complex case 
management addresses the individual 
needs of the sickest individuals. 
Because each of these programs has 
been developed in isolation from 
the others, they inadvertently have 
contributed to the fragmentation of 
health care described. 
With this in mind, a new definition 
of care management (CM) is apropos. 
CM is the integration of traditional 
wellness, disease management (also 
known as “care gap closure”), complex 
care management, and care transition 
programs into a series of patient-
centered interventions that use 
elements from each as appropriate. 
CM recognizes that services are 
simultaneously “horizontal” and 
“vertical.”  “Horizontal” refers to the 
natural progression of disease along 
a continuous time line, generally 
from healthy to sick. At any given 
point along the continuum, there are 
associated interventions from any or all 
of the care management groups. Many 
interventions are “vertical,” reflecting 
the severity of disease, from low-risk 
primary care to complex specialty care. 
In a practical sense, the CM 
coordinators who interact with patients 
must be educated in the natural history 
of the disease and the interventions 
traditionally applied to each group. 
At any given time a patient may need 
guidance in all of the groups. For 
instance, a patient with congestive heart 
failure may require: 
•  Wellness advice about a pap test and 
immunizations.
•  Disease management services for 
hypertension and obesity.
Redefining Care Management to Address Increasing Fragmentation in Health Care
By Michael Kobernick, MD, MS
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•  Complex case management 
services to help with medication 
reconciliation, daily weights, and 
regular physician appointments to 
avoid admissions. 
Integrating the education and services 
provided by a CM coordinator is the 
best way to improve outcomes and 
reduce costs. 
The effectiveness of the CM 
coordinator is dependent on the ability 
of our health care system to aggregate 
patient information in electronic 
health records and to make this 
information available to all providers 
at any time. In the example presented, 
such information sharing could have 
prevented many of the errors. The 
chest X-ray would have been available 
to the emergency physician, who would 
have noticed an artifact masquerading 
as air in the chest. A detailed history 
of allergies would have avoided the 
allergic reaction.  
In addition to personal health 
data, aggregate information from 
populations must be collected in a 
format that allows for group analysis, 
the generation of targeted population 
interventions, and the ability to 
measure the success of such programs. 
Data collection and reporting are 
essential elements in curing the 
problem of fragmentation in delivering 
care to individuals in the population.
Poor communication with the 
individual and family is another 
source of fragmentation. Who among 
us has not experienced confusion 
and concern when told we need 
certain serious health care services? 
People frightened by the lack of 
empathetic communication often seek 
reassurance in settings that add to the 
fragmentation of care. Integration 
of CM includes attention to the 
relationship of the care team with 
the individual patient and his or her 
family. Beyond clinical protocols, CM 
coordinators need help in acquiring 
the skills necessary for developing 
a trusting relationship with the 
patient. The essence of any healing 
relationship hinges on the balance 
between the clinical science and 
personal interaction.
The next iteration of health care 
reforms must seek to cure the 
fragmentation that exists in our 
current system. This requires that 
we understand the natural history 
of disease, matching interventions 
to the course of the illness with 
compassionate understanding.
Michael Kobernick, MD, MS, is Chief 
Medical Officer at Ascension Health - 
SmartHealth. He can be reached at: 
michael.kobernick@ascensionhealth.org.
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